New cancer drugs help Johnson & Johnson top profit estimates
October 17, 2017 at 15:00 PM EDT
(Reuters) - Johnson & Johnson posted better-than-expected third-quarter earnings, raising its full-year forecast due to growth from new cancer drugs and high-margin treatments picked up in its $30 billion acquisition of Actelion earlier this year.